Clinical trial NCT05276830: An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of BXCL501 For The Treatment of Agitation Associated With Dementia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Agitation
Dementia
Lead sponsor: BioXcel Therapeutics Inc
Sponsor class: INDUSTRY
Collaborators: name: Cognitive Research Corporation
First posted: 2022-03-11
Enrollment: 5
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Study will randomize subjects 1:1:1 to receive BXCL501 40 μg, BXCL501 60 μg, or matching placebo film
Primary purpose: TREATMENT

Brief summary: A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation associated with all forms of dementia (i.e., probably Alzheimer's Disease, vascular dementia; mixed; frontotemporal dementia) excluding Parkinson's-Related Dementia and Lewy Body Dementia.

Detailed description: The study will enroll at least 75 subjects to receive a single film consisting of BXCL501 40 μg dose, BXCL501 60 μg dose, or matching placebo film. Subjects must reside in a residential care facility and must require at least moderate assistance with activities of daily living (e.g., bathing, dressing, and toileting). The subject must be able to self-administer the film to participate in the study.

The effects of BXCL 501 on acute agitation will be assessed by the following scales: PEC, PAS, ACES, and CGI-I.

Eligibility criteria: Inclusion Criteria:

1. Individuals diagnosed with any form of dementia (i.e., probable Alzheimer's Disease; vascular dementia; mixed; frontotemporal dementia)
2. Subjects who have met DSM-5 criteria for dementia (major neurocognitive disorder) who have instances of acute psychomotor agitation.
3. History of psychomotor agitation (e.g., kick, bite, flailing) to the point that it impairs social activities, requires staffing, or medical intervention, or impairs ability for functional activities of daily living.
4. Subjects are expected to exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior.
5. Subjects who have a score of ≤16 on the Mini-Mental State Exam (MMSE).
6. Subjects with a remote (\>5 years) history of stroke may be included, regardless of size/location.
7. Subjects who read, understand, and provide written informed consent, or who have a legally authorized representative (LAR).
8. Subjects who are deemed to be medically appropriate for study participation by the principal investigator.
9. Subjects who are at their current location for at least 14 days before screening and plan to remain at the same location for the duration of the study.
10. Subjects who have the capability to participate in the study and self-administer the investigational product.
11. Subjects who are on a stable concomitant medications regimen for the treatment of any concurrent conditions for at least one month prior to the screening visit.

Exclusion Criteria:

1. Subjects who have dementia associated with Parkinson's disease and/or Lewy Body Disease are excluded.
2. Subjects suffering from alcohol and/or substance abuse.
3. Subjects with agitation caused by acute intoxication must be excluded.
4. Subjects with significant risk of suicide or homicide per the investigator's assessment.
5. Subjects who have hydrocephalus, seizure disorder, or history of significant head trauma, subarachnoid bleeding, brain tumor, encephalopathy, meningitis, or focal neurological findings, with a recent (1 year) large (non-microvascular) stroke who may be considered medically unstable or in recovery must be excluded.
6. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years.
7. Subjects with laboratory or ECG abnormalities.
8. Subjects with serious, unstable, or uncontrolled medical illnesses must be excluded.
9. Subjects who have received an investigational drug within 30 days prior to Screening must be excluded.
10. Subjects who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving dexmedetomidine must be excluded.
11. Subjects whose agitation is attributed to pain or infection, delirium, concomitant medications, environmental conditions, or another psychiatric condition or medical condition as determined by the investigator.

Primary outcomes:
measure: Change in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score
timeFrame: 120 minutes
Secondary outcomes:
measure: Change From Baseline for Pittsburgh Agitation Scale
timeFrame: 120 minutes
measure: Change From Baseline for Agitation-Calmness Evaluation Scale
timeFrame: 120 minutes
measure: Clinical Global Impression - Improvement
timeFrame: 120 minutes
Other outcomes:
Locations:
city: North Miami
country: United States
facility: Bioxcel Clinical Research Site
state: Florida
city: Springfield
country: United States
facility: Bioxcel Clinical Research Site
state: Massachusetts
city: Toms River
country: United States
facility: BioXcel Clinical Research Site
state: New Jersey
Study officials:
affiliation: BioXcel Therapeutics
name: Robert Risinger, MD
role: STUDY_CHAIR
References: